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ABSTRACT
Background and objective: there are no studies in the litera-
ture about the effectiveness of adalimumab biosimilar ABP 
501 in Crohn’s disease. The aim of this study was to evaluate 
its effectiveness and safety. 
Methods: an observational study was performed in Crohn’s 
disease patients treated with ABP 501, with the classic in-
duction and maintenance regimen and in Crohn’s disease 
patients who were switched from the adalimumab origina-
tor to ABP 501.
Results: eighty-seven patients were included in the study, of 
which 25 were naïve to the adalimumab originator and 62 
were switched to ABP 501. In adalimumab-naïve patients, cli-
nical response at three months was 60 % (15/25) and clinical 
remission at three months was 56 % (14/25). At six months, 
95.2 % (59/62) of the patients switched to ABP 501 were still 
in therapy, without a significant increase of clinical activity 
(Harvey-Bradshaw index from 3.4, 95 % CI = 2.4-4.4, to 3.8, 
95 % CI = 2.7-4.9, p = 0.23) and inflammatory biomarkers 
(C-reactive protein from 4.2 mg/l, 95 % CI = 2.5-5.9 mg/l, to 
3.6 mg/l, 95 % CI = 2.2-5 mg/l, p = 0.32). There were no unex-
pected adverse events during the study period.
Conclusions: our results support ABP 501 as an effective 
and well-tolerated drug, with a good interchangeability with 
its originator for the treatment of Crohn’s disease.
Keywords: Amgevita®. Anti-TNF. Inflammatory bowel di-
sease.
INTRODUCTION
Crohn’s disease (CD) is a chronic condition with progressi-
ve damage to the gastrointestinal tract, which affects the 
quality of life of patients (1). We are still far from being 
able to cure this disease, but we have a growing number 
of drugs to control flares and prevent complications due to 
its natural history (2). Anti-tumor necrosis factor (anti-TNF) 
(TNF is a pleotropic pro-inflammatory cytokine) were the 
first approved biological drugs in CD. Among this class of 
drugs, adalimumab, a fully human monoclonal antibody 
directed against soluble and membrane-bound TNF, is hi-
ghly effective in CD (3).
Although the use of biologics in CD has made it possible to 
reach targets such as improvement in the quality of life and 
clinical and endoscopic response in patients who have fai-
led previous therapies (steroids, thiopurines, etc.) (4), they 
entail an increasing cost on the national health systems (5). 
Biosimilar drugs, which are biological drugs being develo-
ped as similar therapeutic alternatives to their originators, 
respond precisely to this need. However, there are few stu-
dies that support their use in inflammatory bowel disease 
(IBD), especially regarding adalimumab.
The use of biosimilars of adalimumab in CD, which are 
now widely used in the clinical practice, is based on the 
concept of extrapolation of the results obtained in rheu-
matoid arthritis (6) and in psoriasis (7). However, there is 
no study about the efficacy and safety in CD of the biosi-
milars approved in Europe and in the United States, such 
as ABP 501. The concept of extrapolation is unique to biosi-
milars. Studies about the effectiveness of this biosimilar of 
adalimumab in CD would allow us to answer some of the 
doubts raised regarding the concept of extrapolation (8-11). 
ABP 501 (Amgevita®; Amgen Inc., Thousand Oaks, CA, USA) 
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baseline and complete tapering of systemic corticoste-
roids. For patients with active perianal fistulising disease, 
fistula response was defined by a reduction of the num-
ber of draining fistulae ≥ 50 %, as assessed by physical 
examination without the need for surgical intervention. 
Fistula remission was defined as a complete absence of 
fistula drainage and closure of all fistulae on physical 
examination (16). Due to the observational design of the 
study and the short follow-up (six months), pelvic mag-
netic resonance imaging that, in our clinical practice, is 
performed one year after the start of an anti-TNF was not 
included (17).
•  For patients who switched to ABP 501: drug retention at 
24 weeks.
Secondary outcomes were:
•  Clinical remission rate at week 12 (for patients treated 
with ABP 501 as first adalimumab). Clinical remission was 
defined as HBI ≤ 4 points and complete tapering of syste-
mic corticosteroids (18). 
•  HBI and CRP reduction at week 12 (for patients treated 
with ABP 501 as first adalimumab), no significant change 
in HBI and CRP values at week 24 (for patients who swit-
ched to ABP 501).
•  Analysis of predictors of drug discontinuation in the who-
le population (i.e., combination therapy with azathioprine, 
previous anti-TNF use, sex, age, disease duration).
•  Adverse events, defined as new events that began during 
or following the first and within two months after the last 
dose of ABP 501. With regard to the side effects, all those 
that occurred during the follow-up period were conside-
red, regardless of the probability that they were conse-
quent to the use of ABP 501.
Statistical analysis
Continuous variables were reported as the mean (range). 
The normality of the data was evaluated by the D’Agosti-
no-Pearson test. The comparison of paired measurements 
was performed using the Student’s t test for paired mea-
surements. The cumulative retention rate of ABP 501 was 
calculated with the Kaplan-Meier survival curves. Multiva-
riable Cox proportional hazards regression models were 
used to identify the predictors of ABP 501 discontinuation. 
A p value of less than 0.05 was considered as significant. 
The statistical analysis was performed with the MedCalc 
Statistical Software version 18.9.1 (MedCalc Software bvba, 
Ostend, Belgium; http://www.medcalc.org; 2018).
Ethical considerations
The ethical committee of our institution approved the analy-
sis of the data of all patients treated with adalimumab and 
the correlation with clinical parameters.
RESULTS
Eighty-seven patients were included in the study, of which 
25 were naïve to adalimumab originator and 62 were swit-
ched to ABP 501. The demographic and clinical characte-
ristics of the two study populations are shown in table 1.
is a biosimilar of the adalimumab originator (Humira®; Abb-
Vie Inc., North Chicago, IL, USA) approved for all the in-
dications of its originator. The similarity between ABP 501 
and adalimumab has been demonstrated by means of an 
analytical assessment and human pharmacokinetic evalua-
tion (12).
The aim of this study was to analyze, for the first time, the 
effectiveness and safety of ABP 501 in CD patients naïve to 
adalimumab and the biosimilar adalimumab maintenance 
in CD patients who switched from the adalimumab origi-
nator.
METHODS
A prospective observational study was performed at the 
gastroenterology clinic of the Turin university hospital be-
tween November 2018 and May 2019, according to regional 
indications:
•  All CD patients who began adalimumab were treated with 
ABP 501.
•  All CD patients with stabilized disease (clinical and bioche-
mical remission from at least six months) treated with the 
adalimumab originator were switched to ABP 501. Accor-
ding to the position paper of the Italian Group for the Study 
of Inflammatory Bowel Disease (IG-IBD) and ECCO, we ex-
plained to the patient that when a biosimilar is approved 
by the European Medicines Agency (EMA) according to the 
strict regulations applied to this drug class, we consider it 
as equivalent to its originator. Switching from the origina-
tor to a biosimilar is acceptable, because this approach is 
safe, effective and leads to a significant cost reduction for 
the health care system and, subsequently, to the possibility 
of treating more patients (13,14).
All CD patients who began ABP 501 as a first adalimu-
mab treatment (160 mg, 80 mg after 14 days, 40 mg every 
14 days) were prospectively followed up at three months; 
all CD patients who switched to ABP 501 (40 mg every 
14 days) were prospectively followed up at six months. 
The following parameters were prospectively collected at 
every visit: previous biological treatments, smoking habits, 
Harvey-Bradshaw index (HBI), concomitant treatments, 
adalimumab retention, adalimumab dose escalation, clini-
cal response and clinical remission (for patients who began 
ABP 501 as first adalimumab treatment), C-reactive protein 
(CRP), perianal involvement, CD-related hospitalization, 
CD-related intestinal surgery, anal surgery and adverse 
events. Given the observational nature of the study, cal-
protectin was not included because of the cost to patients.
Inclusion criteria were: CD diagnosed according to ECCO cri-
teria (15), age ≥ 16 years and initiation of therapy with ABP 
501. Exclusion criteria was follow-up duration of less than 
three months for adalimumab-naïve patients and less than six 
months for patients who switched to ABP 501.
Primary outcomes were: 
•  For patients treated with ABP 501 as the first adalimu-
mab: clinical response rate at 12 weeks. Clinical response 
was defined as a ≥ 3-point decrease in HBI compared to 
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Clinical effectiveness of ABP 501 in adalimumab-naïve pa-
tients
The cumulative retention rate of ABP 501 in adalimu-
mab-naïve patients is shown in figure 1.
After three months, 96 % (24/25) of the patients were still 
on ABP 501 therapy, and after six months, 92 % (23/25) of 
the patients were still on ABP 501 therapy. The reason for 
discontinuation was adverse events in all patients, such as 
backache, headache and vomiting in one patient and abdo-
minal pain in the other patient. Clinical response at three 
months was 60 % (15/25) (Fig. 2).
Clinical remission at three months was 56 % (14/25). The 
mean HBI score at baseline was 6.1 (95 % confidence inter-
val, CI = 4.3-7.9), which decreased at week 12 (4.7, 95 % CI 
= 2.6-6.8, p = 0.10). The mean of the CRP values at baseline 
was 14.9 mg/l (95 % CI = 4.8 mg/l-25.1 mg/l), which decrea-
sed at week 12 (6.2 mg/l, 95 % CI = 2.4-10.1 mg/l, p = 0.11). 
The ABP 501 dose was escalated in two patients (8 %).
Clinical effectiveness of ABP 501 in patients who switched 
from adalimumab originator
The cumulative retention rate of ABP 501 in patients who 
switched from adalimumab originator is shown in figure 3.
After six months, 95.2 % (59/62) of the patients were still on 
ABP 501 therapy. The reason for discontinuation was secon-
dary failure in all patients. The mean HBI value at baseline 
was 3.4 (95 % CI = 2.4-4.4) and did not change significantly 
after six months of therapy (3.8, 95 % CI = 2.7-4.9, p = 0.23). 
The mean of the CRP values at baseline was 4.2 mg/l (95 % 
CI = 2.5-5.9 mg/l) and did not change significantly after six 
months of therapy (3.6 mg/l, 95 % CI = 2.2-5 mg/l, p = 0.32). 
The ABP 501 dose was escalated in three patients (4.8 %).
Table 1. Demographic and clinical characteristics of patients treated with ABP 501, naïve to adalimumab (n = 25) or 
who switched from adalimumab originator to ABP 501 (n = 62)
Characteristics Patients naïve to adalimumab Patients who switched to ABP 501
Sex, n ( %) 
 Male
 Female
17 (68)
8 (32)
39 (62.9)
23 (37.1)
Age at ABP 501 first dose, mean years (range) 45.9 (18-66) 42.8 (16-68)
Smoking habits n ( %) 
 Current
 Ex-smokers
 Never
9 (36)
6 (24)
10 (40)
29 (46.8)
13 (21)
20 (32.3)
Disease duration, mean years (range) 16.5 (0-46) 17.3 (1-49)
HBI at first treatment, mean score (95 % CI) 6.1 (4.3-7.9) N/A
Perianal involvement, n ( %) 5 (20) 13 (21)
CI: confidence interval; N/A: not applicable (all patients were in clinical remission).
Fig. 1. ABP 501 retention rate in patients naïve to 
adalimumab.
Fig. 2. Clinical response at week 12 to ABP 501 in patients 
naïve to adalimumab.
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Factors predicting drug discontinuation in the whole po-
pulation
The Cox proportional-hazards regression analysis for pre-
dictors of drug discontinuation is reported in table 2. Fema-
le sex ( p = 0.047) was associated with a worse outcome of 
drug persistence.
Safety
Twenty-two patients experienced at least one adverse event 
(25.3 %). Four of the patients suffered from a rash; eight, 
abdominal pain; four, diarrhea; five, arthralgia; five, vomi-
ting; one, anemia; one, rectal bleeding; two, headaches; 
one, bronchitis; one, herpes simplex type 1 clinical reac-
tivation; three, fever; and one, weight loss. Some patients 
experienced more than one side effect. There were no cases 
of malignancy, tuberculosis or death reported during the 
study. The CD-related hospitalizations rate during ABP 501 
therapy was 1.1 % (n = 1/87). No CD-related surgery events 
were recorded during the study.
DISCUSSION
In recent years, the interest in biosimilar drugs has cons-
tantly grown thanks to the great economic savings that 
their use entails. Generic drugs are identical from the point 
of view of the active ingredient with respect to the drugs 
from which they derive. However, biosimilars cannot be 
identical to their originators because of the complex and 
proprietary protein structure of which they are made, re-
quiring unique cell lines (19). Biosimilars are not identical 
to their originators.
The efficacy and safety of the adalimumab biosimilar ABP 
501 has been established in multi-center, randomized, clini-
cal trials (RCTs) in psoriasis (7) and rheumatoid arthritis (6). 
Therefore, there is a great expectation for data concerning 
the effectiveness of adalimumab biosimilars in IBD. Unfor-
tunately, to date, the studies in this regard are absolutely 
lacking. This study describes for the first time the efficacy 
and adverse events of the adalimumab biosimilar ABP 501 
in a population of 87 CD patients, of which 25 are naïve to 
adalimumab and 62 switched from the adalimumab origi-
nator to ABP 501. 
A significant proportion of patients treated with ABP 501 
showed clinical benefit until the end of follow-up. The rate 
of clinical remission at week 12 was 56 %, which was com-
parable to the rates of the adalimumab originator in the 
CHARM trial at week 26 (40 %) (3) and in the CLASSIC trial 
at four weeks (36 %) (20). The same was true for the data 
regarding drug retention rate, which was 92 % at six mon-
ths for the patients that had received an induction dose of 
160 mg of ABP 501. This was comparable with data from 
the real-life experience of adalimumab originator (81 % at 
12 months [21]). 
HBI and CRP values decreased in a clinical significantly 
way after 12 weeks of ABP 501 160 mg first dose compa-
red to baseline. However, these differences did not reach 
statistical significance due to the sample size ( p = 0.10 
and p = 0.11, respectively). Only one study analyzed the 
efficacy of one adalimumab biosimilar (Exemptia®) in IBD 
patients in a real-life setting in India (22). This retrospective 
study only included patients (49 CD) treated with Exemptia® 
as a first adalimumab induction therapy. At week 8, 47 % 
Fig. 3. ABP 501 retention rate in patients who switched 
from the adalimumab originator.
Table 2. Cox proportional-hazards regression analysis for predictors of ABP 501 discontinuation 
Characteristics p value
Age 0.78
Disease duration 0.11
Experienced to adalimumab originator 0.97
Female 0.047
Current smoker 0.66
Infliximab-naïve 0.97
History of perianal disease 0.92
Combinational therapy with azathioprine 0.33
Steroids at baseline 0.97
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of CD patients were in clinical remission and the clinical 
response was 57 %; at 26 weeks, 41 % of patients were in 
clinical remission. During the two years of follow-up, 17 % 
of patients underwent surgery and 10 % had serious adver-
se events (three patients developed pulmonary tuberculo-
sis). No studies about interchangeability of an adalimumab 
biosimilar, including ABP 501 with its originator in IBD have 
been published. 
In our study, 62 CD patients switched from the adalimumab 
originator to ABP 501 and 95.2 % were still on ABP 501 
therapy after six months; data confirm those of the biosi-
milar of infliximab CT-P13 (23). Female sex as a prognostic 
factor of precocious ABP 501 discontinuation confirmed 
what had already been reported for the adalimumab ori-
ginator (21), but the possible biological explanation it is 
not yet known. With regard to adverse events, there were 
no unexpected safety findings including death during the 
study period. Our results suggest that, at least in the short-
term, treatment with ABP 501 was generally well-tolerated 
in CD and the safety profile of ABP 501 seems to be not 
inferior to that of the adalimumab originator. Our results 
support that ABP 501 is interchangeable with its originator 
in the treatment of CD.
A potential limitation of our study is the relatively small 
sample size, which limited the generalizability of our fin-
dings. The observational design of this study could have 
overestimated the efficacy and underestimated the rate of 
side effects of ABP 501 in CD compared to RCTs. However, 
these are unlikely to be performed in this setting due to 
their high costs as long-term surveillance would be nee-
ded to further assess the safety profile. Data on endoscopic 
effectiveness were very limited, as follow-up colonoscopy 
was performed in only a few cases at various time points. 
Thus, they have not been reported in our analysis. With re-
gard to patients who switched from the originator to a bio-
similar, a concern about the nocebo effect should be raised 
(24). According to the IG-IBD position paper (13), reliable, 
up-to-date information to help patients understand biosi-
milars and enable them to make informed choices about 
their treatment options was provided. Thus, this should 
have limited the nocebo effect (25). Finally, ABP 501 was not 
directly compared with its originator and as the use of ABP 
501 derived from a regional indication, it was impossible to 
directly compare ABP 501 and the adalimumab originator 
in two comparable patient cohorts. 
Despite these limitations, our data provide meaningful in-
formation that reflects the actual experience (effectiveness, 
safety) of the short-term treatment with ABP 501 in a real-li-
fe cohort of CD patients. Another strength of our study is 
that it was not supported by Amgen Inc. Thus, we have no 
conflicts of interest compared to the studies about the effi-
cacy of ABP 501 in psoriasis (7) and rheumatoid arthritis (6). 
In conclusion, our findings support the use of the adalimu-
mab biosimilar ABP 501 in CD as an effective and well-tole-
rated drug, at least in the short-term. These data contribute 
to the confirmation of the similarity between ABP 501 and 
the adalimumab originator. Further multicenter studies with 
a larger sample size and a longer follow-up are needed to 
confirm our preliminary results. 
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